Disopyramide (diso) is used in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility without affecting calcium transients. We investigated concomitant use and withdrawal in patients with oHCM.
SAFETY AND OUTCOMES OF CONCOMITANT AFICAMTEN AND DISOPYRAMIDE USE AND WITHDRAWAL IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: AN ANALYSIS OF REDWOOD-HCM COHORT 3, SEQUOIA-HCM, AND FOREST-HCM TRIALS / Masri, Ahmad; Abraham, Theodore P.; Nassif, Michael; Barriales-Villa, Roberto; Bilen, Ozlem; Coats, Caroline; Elliott, Perry M.; Massera, Daniele; Olivotto, Iacopo; Oreziak, Artur; Owens, Anjali Tiku; Saberi, Sara; Solomon, Scott; Tower-Rader, Albree; Heitner, Stephen B.; Jacoby, Daniel; Kupfer, Stuart; Malik, Fady I.; Melloni, Chiara; Wei, Jenny; Wohltman, Amy; Maron, Martin S.; Sherrid, Mark V.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - ELETTRONICO. - 85:(2025), pp. 0-0. [10.1016/s0735-1097(25)01644-4]
SAFETY AND OUTCOMES OF CONCOMITANT AFICAMTEN AND DISOPYRAMIDE USE AND WITHDRAWAL IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: AN ANALYSIS OF REDWOOD-HCM COHORT 3, SEQUOIA-HCM, AND FOREST-HCM TRIALS
Olivotto, Iacopo
;
2025
Abstract
Disopyramide (diso) is used in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility without affecting calcium transients. We investigated concomitant use and withdrawal in patients with oHCM.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
